ExOne Opens State-of-the-Art Metal 3D Printing Adoption Center in Europe, Expands Engineering Support
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced it has opened a Metal 3D Printing Adoption Center at its European headquarters in Gersthofen, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005298/en/
Eric Bader, Managing Director of ExOne GmbH, says the launch of ExOne's Metal 3D Printing Adoption Center is driven by increased interest by European manufacturers in metal binder jet 3D printing. ExOne’s Adoption Centers now print sand molds and cores for metalcasting customers, as well as metal benchmarks for its metal binder jetting engineering consulting services. (Photo: Business Wire)
The mission of ExOne’s Adoption Centers, which have locations in the U.S., Germany, and Japan, is to allow customers to try binder jet 3D printing for their designs before they decide to buy an ExOne 3D printing system for their own production.
The investment announced today represents an expansion of ExOne’s longtime Adoption Center in Europe, which 3D prints sand molds and cores for metalcasting customers. ExOne’s Metal Adoption Center now offers manufacturers end-to-end engineering services for direct-metal binder jet 3D printing, including benchmarks, design support, and materials, process, and work cell development.
“Now, manufacturers throughout Europe can benefit from locally produced binder jetted metal designs and benchmarks, along with world-class engineering consultation and support,” said John Hartner, ExOne’s CEO. “We encourage manufacturers to take advantage of the high speed, low cost, and industry-leading quality that our patented binder jetting technology can deliver for even the most complex designs.”
“Our centralized location outside of Munich gives manufacturers the opportunity to see metal binder jetting in action and work closely with our expanded metal team on precision metal parts projects,” said Eric Bader, Managing Director, ExOne GmbH. “This expansion is supported by increased interest in metal binder jetting in Europe as the technology matures.”
High-Quality Metal Parts Key Focus of New Center
Binder jetting is a high-speed method of 3D printing in which an industrial inkjet printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final part must be sintered in a furnace to fuse the particles together into a high-density solid object.
All new ExOne metal printers, such as the X1 160Pro manufactured on-site in Gersthofen, are now offered with the company’s patented Triple Advanced Compaction Technology (ACT), which delivers industry-leading accuracy, density, and repeatability in binder jet printing.
ExOne has now qualified more than 20 metal, ceramic, and composite materials for its binder jetting process. More than half of those materials are single-alloy metals, such as 17-4PH, 316L, 304L, M2 Tool Steel, Inconel 718, and more. Most recently, ExOne announced that 6061 aluminum is now a Customer-Qualified material, and titanium is now fast-tracked for qualification in partnership with a global medical device firm.
ExOne’s New Metal 3D Printing Adoption Center will initially focus on the delivery of small-to-medium parts with quality similar to Metal Injection Molding (MIM) in 316L and 17-4PH, with other materials available. To exploring having your part or product metal 3D printed with ExOne technology, contact ExOne through exone.com/EMEAmetal or +49 821 65063 238.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005298/en/
Contact information
Sarah Webster
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom